Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 85 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Non Alcoholic Fatty Liver Disease (NAFLD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Non Alcoholic Fatty Liver Disease (NAFLD) Overview 8
Therapeutics Development 9
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 9
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis 10
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Development by Companies 11
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Investigation by Universities/Institutes 13
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Development by Companies 17
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Investigation by Universities/Institutes 18
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 19
F. Hoffmann-La Roche Ltd. 19
Merck & Co., Inc. 20
Novartis AG 21
Daewoong Pharmaceutical Co., Ltd. 22
Orchid Chemicals & Pharmaceuticals Ltd 23
Phynova Group Ltd 24
Raptor Pharmaceuticals Corp. 25
Phenex Pharmaceuticals AG 26
Metabolic Solutions Development Co. 27
Zafgen Inc. 28
Verva Pharmaceuticals Limited 29
Galmed International Ltd. 30
TCM Biotech International Corp 31
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 38
Assessment by Molecule Type 39
Drug Profiles 41
oltipraz - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
cysteamine DR - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Aramchol - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pradigastat sodium - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Px-102 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BLX-1002 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MB-12066 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Px-104 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MK-4074 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
RO-5093151 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DWP-10292 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
PYN-22 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
methazolamide - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
VVP-100-X - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MSDC-0602 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ZGN-839 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Px-103 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
TCM-606F - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Antisense Oligonucleotides Targeting ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MAT-8800 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Non Alcoholic Fatty Liver Disease (NAFLD) - Recent Pipeline Updates 69
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 80
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 81
Featured News & Press Releases 81
Apr 28, 2014: Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies 81
Apr 08, 2014: Transgenomic Announces Collaboration with Raptor Pharmaceuticals for Genetic Testing Services 81
Dec 17, 2012: La Jolla Pharma's GCS-100 Demonstrates Statistically Significant Reduction In Liver Fibrosis In Preclinical Study 81
Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102 82
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 85
Disclaimer 85

List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2014 9
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 19
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Merck & Co., Inc., H2 2014 20
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H2 2014 21
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 22
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H2 2014 23
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Phynova Group Ltd, H2 2014 24
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Raptor Pharmaceuticals Corp., H2 2014 25
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Phenex Pharmaceuticals AG, H2 2014 26
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Metabolic Solutions Development Co., H2 2014 27
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zafgen Inc., H2 2014 28
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Verva Pharmaceuticals Limited, H2 2014 29
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed International Ltd., H2 2014 30
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 37
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Recent Pipeline Updates, H2 2014 69
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2014 80